FOAMIX PHARMACEUTICALS LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 14, 2020, Foamix Pharmaceuticals Ltd. (the "Company") issued a press release entitled "Foamix Announces AMZEEQTM (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S." A copy of the press release is attached as Exhibit 99.1 to this report.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.   Description

  99.1          Press release entitled "Foamix Announces AMZEEQTM (minocycline)
              Achievement of Preferred Status on Express Scripts National Preferred
              Formulary, One of the Largest Commercial Formularies in the U.S.," dated
              January 14, 2020.

© Edgar Online, source Glimpses